A new study from Italian and German researchers builds the most detailed "map" yet of the mouse pancreas, cell by cell.
Along the way, it reveals that the organ's most abundant cells are far more diverse than we thought, and that they carry a lasting molecular "memory" of past inflammation that could help explain why the pancreas is vulnerable to cancer.

A new study published in Cancer Immunology Research, one of the official journals of the American Association for Cancer Research (AACR), identifies a previously unrecognized population of macrophages in human pancreatic cancer and provides new insights into how the tumor microenvironment shapes immune cell behavior.

One of the biggest challenges in treating pancreatic cancer is that tumors often stop responding to therapy, sometimes very quickly. A new study published in PNAS (April 2026), with the contribution of the I-PCC co-founders Dr. Carmine Carbone and Dr. Vincenzo Corbo, sheds important light on why this happens with a promising class of targeted drugs, and points toward a potential solution.

A large international clinical trial has just delivered what many in the pancreatic cancer community have been waiting years for: a new treatment that significantly outperforms chemotherapy in patients whose cancer has already progressed on a first treatment.

The Italian Pancreatic Cancer Community (I-PCC) is pleased to announce the receipt of €110,000 by Fondazione Nadia Valsecchi in support of scientific research on pancreatic cancer.

A new research project led by Dr. Alessandro Carrer at the University of Padova, and cofounder of I-PCC, has been selected for funding by the Wereld Kanker Onderzoek Fonds, a charity in the  World Cancer Research Fund (WCRF) International network.

Every year, November is dedicated to raise awareness about pancreatic cancer, one of the most challenging diseases to diagnose and treat.

During the recent World Pancreatic Cancer Coalition (WPCC) member call, Dr. Anna Berkenblit, Chief Scientific and Medical Officer at PanCAN, delivered a comprehensive overview of the current state of pancreatic cancer research.

During the latest I-PCC symposium, we officially opened the network to “Affiliated Labs”, laboratories whose principal investigators or teams actively participate in or contribute to I-PCC, and are distinct from the “Founder Labs”.

The second symposium of the Italian Pancreatic Cancer Community (I-PCC) was held on June 4th 2025 in the beautiful setting of CNR Nanotec in Lecce, an exceptional venue that welcomed over 130 participants and featured 21 scientific presentations, many of which were delivered by young researchers, PhD students, and postdocs. The event was a resounding success, reaffirming the energy and cohesion of a growing community deeply committed to the fight against pancreatic cancer.

The Italian Pancreatic Cancer Community (I-PCC) is an online platform that connects Italian scientists working in basic and translational pancreatic cancer research. Established in 2021 with the support of Fondazione Nadia Valsecchi, a non-profit organization with over 10 years of experience supporting research, patients, families, and public awareness, the I-PCC aims to foster collaboration and accelerate progress in the fight against pancreatic cancer.